# Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

> **NCT00466232** · PHASE1 · COMPLETED · sponsor: **HealthPartners Institute** · enrollment: 16 (actual)

## Conditions studied

- Small Cell Carcinoma
- Lung Cancer

## Interventions

- **DRUG:** Topotecan
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00466232
- **Lead sponsor:** HealthPartners Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-12
- **Final completion:** 2010-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2015-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00466232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00466232, "Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00466232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*